CYMA News Alert Cymabay Therapeutics (CYMA) 6.4500 09/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cymabay Therapeutics (CYMA) 6.4500 $CYMA

CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"
Marketwire - Mon Jun 16, 8:02AM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Wednesday, June 18, 2014 under the symbol "CBAY". The company's common stock will continue to trade on the Over the Counter Bulletin Board, under the symbol "CYMA", until the market close on Tuesday, June 17, 2014.

CymaBay reports launch of Phase 2b study of arhalofenate in gout patients
M2 - Thu Mar 27, 5:19AM CDT
Biopharmaceutical company CymaBay Therapeutics (OTC BB:CYMA) said on Wednesday that it has randomized the first patient under its Phase 2b clinical trial of arhalofenate for for the treatment of gout, a chronic, progressive rheumatic disease.

CymaBay Initiates Arhalofenate Phase 2b Gout Study
Marketwire - Wed Mar 26, 3:21PM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing therapies addressing unmet medical needs in metabolic disease, today announced that it has randomized the first patient in a Phase 2b clinical trial of arhalofenate (MBX-102). Arhalofenate is a dual acting product candidate for the treatment of gout that is targeted to lower serum uric acid (sUA) and reduce the incidence of flares.

CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer
Marketwire - Mon Mar 03, 8:02AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs in metabolic diseases, today announced that Dr. Pol Boudes has joined the company as Chief Medical Officer. Dr. Boudes brings extensive clinical development experience to CymaBay, including expertise in all phases of clinical trial design and execution.

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences
Marketwire - Tue Feb 25, 8:05AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA) today announced that Harold Van Wart, President and Chief Executive Officer, will present an overview of the company at investment conferences hosted by Cowen and Company and ROTH Capital Partners.

Mixed Dyslipidemia - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/85sdh6/mixed) has announced the addition of the "Mixed Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Mixed Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Mixed Dyslipidemia. - A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mixed Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mixed Dyslipidemia Overview Therapeutics Development Pipeline Products for Mixed Dyslipidemia - Overview Pipeline Products for Mixed Dyslipidemia - Comparative Analysis Mixed Dyslipidemia - Therapeutics under Development by Companies Mixed Dyslipidemia - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Mixed Dyslipidemia - Products under Development by Companies Mixed Dyslipidemia - Companies Involved in Therapeutics Development Mixed Dyslipidemia - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles evolocumab - Drug Profile Product Description Mechanism of Action R&D Progress bococizumab - Drug Profile Product Description Mechanism of Action R&D Progress INSUPR-001 DR - Drug Profile Product Description Mechanism of Action R&D Progress MBX-8025 - Drug Profile Product Description Mechanism of Action R&D Progress PRC-4016 - Drug Profile Product Description Mechanism of Action R&D Progress CAT-2003 - Drug Profile Product Description Mechanism of Action R&D Progress MAT-9001 - Drug Profile Product Description Mechanism of Action R&D Progress Mixed Dyslipidemia - Recent Pipeline Updates Mixed Dyslipidemia - Dormant Projects Mixed Dyslipidemia - Discontinued Products Mixed Dyslipidemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Pfizer Inc. Pronova BioPharma ASA Intas Pharmaceuticals Ltd. Catabasis Pharmaceuticals, Inc. Matinas BioPharma, Inc. CymaBay Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/85sdh6/mixed About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link
Marketwire - Fri Jan 24, 8:00AM CST
CymaBay Therapeutics, Inc. (OTCBB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs, today announced that its common stock has been cleared for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's OTC Link quotation system under the ticker symbol "CYMA."




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 29

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 62

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 431

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Kennedy Funding Secures $2.85M Loan for Innovative Project

Updated Category News Views 187

Kennedy Funding Closes Major Land Loan for Development Leading private lender, Kennedy Funding, has successfully finalized a significant loan amounting to $2.85 million. This financing supports an exciting mixed-use development project that aims to enhance urban living through the addition of residential units and commercial spaces. Details of the Loan Agreement Secured...

Continue Reading
Expert Opinions on Tesla's Recent Vehicle Pricing Strategy

Updated Category News Views 340

Insightful Perspectives on Tesla's Pricing Changes In the dynamic world of electric vehicles, significant voices like Ross Gerber and Gary Black are raising concerns about Tesla Inc. (NASDAQ: TSLA) and its latest pricing strategy for its affordable Model Y and Model 3 trims. These experts have directed their criticism at Tesla following the company's decision to introduce...

Continue Reading
Analyzing Progress and Challenges in America's New Era

Updated Category News Views 259

Progress and Prosperity in America's New Era The past few months have been quite pivotal for the United States as tremendous advancements unfold under the current administration. The focus this week centers around the concept of progress, showcasing the concrete steps made toward economic stability and increased job opportunities. These developments draw attention to the...

Continue Reading
Lithia & Driveway Anticipates Strong Q1 2025 Earnings Report

Updated Category News Views 240

Lithia & Driveway Anticipates Strong Q1 2025 Earnings Report Lithia & Driveway (NYSE: LAD) is preparing to unveil its first quarter financial results for 2025. The company has announced that these results will be available before the market opens, allowing stakeholders and investors to evaluate the performance of the automotive retailer. Key Date for Earnings Release The...

Continue Reading
Hargreave Hale VCT's Recent Share Purchase Explained

Updated Category News Views 118

Correction on Share Purchase Announcement There has been a clarification regarding a previous announcement from Hargreave Hale AIM VCT PLC concerning a recent transaction in their own shares. Initially made public with an incorrect headline, the announcement aims to ensure all shareholders are accurately informed about the company's activities. Details of Share Purchase...

Continue Reading